Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridoxamine for Oxalate Excretion in Stone Disease and Hyperoxaluria
NCT00490113Phase 2Withdrawn
- Sponsor
- University of Kansas Medical Center
- Start
- Jan 2007
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in nephrolithiasis and Primary hyperoxaluria (PH) comparing Pyridoxamine with Placebo (2 arms). Primary endpoint: Urinary Excretion of Oxalate at Highest Dose at 4 weeks. Planned start Jan 2007; status: withdrawn.
02
Drugs
pyridorin
03
Conditions
nephrolithiasisPrimary hyperoxaluria (PH)
Beyond the preview
Go deeper on NCT00490113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00490113.